国际专家共识:骨科生物制剂使用的最佳实践与不确定性
本研究通过三轮德尔菲法制定关于肌肉骨骼医学中骨科生物制剂使用的国际专家共识声明,由6人工作组初步制定77条声明,经24名国际专家电子问卷调查,最终62条声明中96.8%达成共识(≥70%同意且<20%不同意),但许多声明保留限定性语言,反映制备、剂量和适应症特异性疗效仍存在不确定性。
要点
- 共识覆盖PRP用于膝、髋、盂肱关节炎、跟腱病、外上髁炎、肩袖肌腱炎及半月板修复增强等。
- 骨髓穿刺浓缩物、自体条件血清、羊膜衍生物、基因治疗、外泌体及生物制剂递送方法也达成共识。
- PRP用于肩袖修复增强和自体细胞治疗等主题未达成共识。
核心结论
- 在骨科生物制剂的适当使用场景方面达成了高度共识,但许多声明保留限定性语言,反映制备、剂量和适应症特异性疗效仍存在不确定性。
研究设计与样本
- 由6人工作组制定77条初始声明,24名国际专家参与三轮电子德尔菲调查,每轮参与率100%。
主要发现
- 共识率从第一轮的48.1%(37/77条)逐步增至第三轮的96.8%(60/62条)。
关键数值与推荐
- 共识定义为≥70%同意且<20%不同意。
- 达成共识的类别包括:一般骨科生物制剂和PRP主题;PRP用于膝、髋和盂肱关节炎;PRP用于跟腱病;PRP用于外上髁炎和肩袖肌腱炎;PRP用于半月板修复增强;骨髓穿刺浓缩物;自体条件血清;羊膜衍生物;基因治疗;外泌体;生物制剂递送方法。
- 未达成共识的主题包括PRP用于肩袖修复增强和自体细胞治疗。
临床怎么用
- 临床可参考共识声明中达成共识的适应症使用骨科生物制剂,但需注意许多声明保留限定性语言,反映制备、剂量和疗效的不确定性。
局限性
- 专家认为剂量、制备方法和质量控制仍是存在不确定性和不一致的领域,需要标准化以实现可重复和有意义的治疗效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of orthobiologics has received increasing interest given the potential positive treatment effects on symptoms and tissue regeneration. However, there remains substantial variability surrounding the uses of orthobiologics in clinical practice. The purpose of this study was to create an international Delphi expert consensus statement on the use of orthobiologics in musculoskeletal medicine. METHODS: A working group consisting of 6 members developed 77 initial statements for review by a 24-member panel of international experts. Surveys were conducted in 3 rounds and administered electronically to participants. Participants were asked to respond to each statement using a Likert scale of "strongly disagree," "disagree," "neither disagree nor agree," "agree," and "strongly agree." The final consensus statement included those statements that achieved ≥70% agreement and <20% disagreement. Statements that did not initially achieve consensus were iteratively revised between rounds, which included the incorporation of qualifying language to reflect areas of clinical uncertainty. RESULTS: Sixty-two final statements were utilized in round 3. Each round had 100% participation. Consensus increased sequentially from 48.1% (37 of 77 statements) in round 1 to 96.8% (60 of 62 statements) in round 3. Complete consensus (≥70% agreement and <20% disagreement) was achieved in the following categories: general orthobiologics and PRP (platelet-rich plasma) topics; PRP for knee, hip, and glenohumeral osteoarthritis; PRP for Achilles tendinopathy; PRP for lateral epicondylitis and rotator cuff tendinitis; PRP for meniscus repair augmentation; bone marrow aspirate concentrate; autologous conditioned serum; amniotic derivatives; gene therapy; exosomes; and biologic delivery methods. Some of the topics concerning PRP for rotator cuff repair augmentation and autologous cell-based therapies did not achieve consensus. CONCLUSIONS: A high degree of consensus was achieved across statements concerning appropriate use cases for various orthobiologic therapies. However, many of the adopted statements retained qualifying language, reflecting persistent areas of uncertainty in orthobiologic preparation, dosing, and indication-specific efficacy. Despite high levels of agreement across most categories, experts contended that dosing, preparation methods, and quality control remain areas of uncertainty and inconsistency that require standardization in order to allow for reproducible and meaningful treatment effects.
引用
- Kunze KN, Morgan JT, Gerhold C, et al. An International Expert Consensus Statement Defining the Best Practices and Areas of Uncertainty Concerning the Use of Orthobiologics. J Bone Joint Surg Am. 2026. PMID: 42520131. doi:10.2106/JBJS.26.00723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。